Eiger BioPharmaceuticals, Inc.
(NASDAQ : EIGR)

( )
EIGR After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Loading EIGR News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.96%73.420.9%$713.07m
AMGNAmgen Inc.
0.08%179.321.1%$583.83m
CELGCelgene Corporation
0.97%136.311.1%$571.96m
REGNRegeneron Pharmaceuticals, Inc.
2.83%521.132.7%$511.51m
VRTXVertex Pharmaceuticals Incorporated
-0.23%159.331.9%$392.76m
BIIBBiogen Inc.
-0.18%281.441.2%$388.90m
ALXNAlexion Pharmaceuticals, Inc.
1.97%129.811.9%$272.80m
TSROTESARO, Inc.
4.02%129.0114.7%$168.19m
INCYIncyte Corporation
2.56%133.792.6%$164.97m
ILMNIllumina, Inc.
-1.10%171.973.5%$156.83m
EXELExelixis, Inc.
0.90%26.996.5%$154.24m
CLVSClovis Oncology, Inc.
1.69%85.2718.0%$152.78m
BMRNBioMarin Pharmaceutical Inc.
0.59%87.744.4%$131.34m
KITEKite Pharma, Inc.
4.23%109.8916.1%$121.79m
BLUEBluebird Bio, Inc.
-1.54%95.8019.3%$109.71m

Company Profile

Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA.